Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603880 | 0.80 | PREP (0.49) | PREPSMN1; SMN2RAB9AALDH1A1DRD2 | |
| SCHEMBL13166438 | 0.78 | ALDH1A1 (0.51) | PREPSMN1; SMN2RAB9AALDH1A1DRD2 | |
| SCHEMBL13316351 | 0.78 | ALDH1A1 (0.51) | PREPSMN1; SMN2RAB9AALDH1A1DRD2 | |
| SCHEMBL336766 | 0.76 | OPRD1 (0.53) | PREPFKBP1A | |
| SCHEMBL4738328 | 0.76 | OPRD1 (0.53) | PREPFKBP1A | |
| SCHEMBL337363 | 0.76 | OPRD1 (0.53) | PREPFKBP1A | |
| SCHEMBL25186706 | 0.76 | PREP (0.57) | PREPSMN1; SMN2ALDH1A1FKBP1A | |
| SCHEMBL3336958 | 0.76 | PREP (0.57) | PREPSMN1; SMN2ALDH1A1FKBP1A | |
| SCHEMBL3342656 | 0.76 | PREP (0.57) | PREPSMN1; SMN2ALDH1A1FKBP1A | |
| SCHEMBL25766824 | 0.74 | PREP (0.44) | PREPSMN1; SMN2RAB9ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | SLC6A3, NDUFS5, NDUFB6 | PREP 1477/4885SMN1; SMN2 2090/4885RAB9A 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.